Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy

Endocrine Regulations

Volumn 45, Issue 4, 2011, Pages 199-204

  Ziaran, S ^a   Goncalves, F M ^a   Sen, Breza J ^a  

^a UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

Androgen deprivation therapy; Bone mineral density; Fractures; Prostate cancer

Indexed keywords

CALCIUM; COLECALCIFEROL; RISEDRONIC ACID; RISENDROS; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; CANCER PATIENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; EVALUATION; FEMUR NECK; FRACTURE; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PROSPECTIVE STUDY; PROSTATE CANCER;

ABSORPTIOMETRY, PHOTON; AGED; ANDROGEN ANTAGONISTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCIUM; DIPHOSPHONATES; FEMORAL NECK FRACTURES; FRACTURES, SPONTANEOUS; HIP JOINT; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; VITAMIN D; VITAMINS;

EID: 83455206888     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: 10.4149/endo_2011_04_199     Document Type: Article

References (30)

1. Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K: Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 4, 749-754, 2007. http://dx.doi.org/10.1111/j.1464-410X.2007.07163.x
2. Agarwal MM, Khandelwal N, Mandal AK, Rana SV, Gupta V, Chandra Mohan V, Kishore GV: Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 103, 2042-2052, 2005. http://dx.doi.org/10.1002/cncr.21047
3. Bolla M, Gonzales D, Warde P: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and gosarelin. N Engl J Med 337, 295-300, 1997. http://dx.doi.org/10.1056/NEJM199707313370502
4. Bruder JM, Ma JZ, Basler JW, Welch MD: Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 67, 152-155, 2006. http://dx.doi.org/10.1016/j.urology.2005.07.017
5. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31, 578-583, 2000. http://dx.doi.org/10.1053/hp.2000.6698
6. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA: Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353, 878-882, 1999. http://dx.doi.org/10.1016/S0140-6736(98)09075-8
7. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM: Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 341, 72-75, 1993. http://dx.doi.org/10.1016/0140-6736(93)92555-8
8. Diamond T, Higano C, Smith M, Guise T, Singer F: Osteoporosis in men with prostate cancinoma receiving androgen deprivation therapy: recommendatios for diagnosis and therapies. Cancer 100, 892-899, 2004. http://dx.doi.org/10.1002/cncr.20056
9. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56, 146-156, 2001. http://dx.doi.org/10.1093/gerona/56.3.M146
10. Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K: Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 12, 1071-1075, 2007. http://dx.doi.org/10.1111/j.1442-2042.2007.01911.x
11. Israeli RS, Ryan CW, Jung LL: Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 179, 414-423, 2008. http://dx.doi.org/10.1016/j.juro.2007.09.028
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics. Cancer J Clin 59, 225-249, 2009. http://dx.doi.org/10.3322/caac.20006
13. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res 9, 1137-1141, 1994. http://dx.doi.org/10.1002/jbmr.5650090802
14. Kanis J, Seeman E, Johnell O, Rizzoli R, Delmas P: The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. Osteoporosis Int 16, 456-459, 2005. http://dx.doi.org/10.1007/s00198-005-1861-0
15. Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH: Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162, 2217-2222, 2002. http://dx.doi.org/10.1001/archinte.162.19.2217
16. Liska J, Repiska V, Galbavy S, Polak S, Varga I, Blasko M, Macejova D, Brtko J: Prostate tumours - histological classification and molecular aspects of prostate tumorigenesis. Endocrine Regul 41, 45-57, 2007.
17. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP: Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12, 1761-1768, 1997. http://dx.doi.org/10.1359/jbmr.1997.12.11.1761
18. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA: Fracture risk in patients with prostate cancer on androgen deprivation therapy Osteoporos Int 16, 707-711, 2005. http://dx.doi.org/10.1007/s00198-004-1799-7
19. Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL: Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 14, 3551-3559, 2007.
20. McKiernan JM, Delea TE, Liss M. et al.: Impact of skeletal complications on total medical care costs in prostate cancer patients with bone metastases. Proc Am Soc Clin Oncol 23, 531 (abstract no. 6057), 2004.
21. Melton LJ 3rd, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H: Fracture risk following bilateral orchiectomy. J Urol 169, 1747-1750, 2003. http://dx.doi.org/10.1097/01.ju.0000059281.67667.97
22. Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J: Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69, 500-504, 2007. http://dx.doi.org/10.1016/j.urology.2006.11.002
23. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168, 1005-1007, 2002. http://dx.doi.org/10.1016/S0022-5347(05)64561-2
24. Raffaelli L, Scaramuzzo L, Rossi Iommetti P, Graci C, Maccauro G, Manicone PF: Jaw osteonecrosis related to bisphosphonate treatment of bone metastasis. J Biol Regul Homeost Agents 24, 115-121, 2010.
25. Saad F, Olsson C, Schulman CC: Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 46, 731-739, 2004. http://dx.doi.org/10.1016/j.eururo.2004.08.016
26. Shahinian V, Kuo Y, JL Freeman, Goodwin J: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352, 154-164, 2005. http://dx.doi.org/10.1056/NEJMoa041943
27. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87, 599-603, 2002. http://dx.doi.org/10.1210/jc.87.2.599
28. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 13, 948-955, 2001. http://dx.doi.org/10.1056/NEJMoa010845
29. WHO: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis repot of WHO Study Group. Geneva, 1994: World Health Organization.
30. Ziaran S, Goncalves FM, Wendl J, Trebaticky B, Breza J Sen: Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy. Bratislava Med J 110, 559-562, 2009.